Rheumatology key messagesSLE patients with inactive nephritis have fewer CD8 T cells expressing SLAMF3, SLAMF5 or SLAMF7.SLAMF2-, SLAMF4- and SLAMF7-positive double negative T cells are differentially expressed in lupus patients.There is an increased proportion of SLAMF6 double negative T cells in LN patients non-responding to B-cell depletion therapy.

Introduction
============

SLE is an autoimmune multisystem inflammatory disease that is debilitating and can cause life-threatening organ damage, such as LN. Patients with SLE develop pathogenic autoantibodies that are directed towards a broad range of ubiquitous self-antigens, including dsDNA and nuclear debris from apoptotic cells. These immune complexes (ICs) deposit in organs, and the subsequent influx of inflammatory cells contributes to widespread tissue damage. Owing to its multifactorial aetiology, the immunopathogenesis of SLE is extremely complex and incompletely understood. However, it is widely accepted that loss of B-cell tolerance, in conjunction with CD4 T-cell hyperactivation, is central to lupus pathogenesis. In this context, the signalling lymphocyte activation molecule (SLAM) family receptors have recently emerged as key players in the immune dysregulation underlying lupus pathogenesis \[[@kex078-B1], [@kex078-B2]\]. Studies using knockout mice deficient in SLAM family receptors and SLAM-associated protein (SH2D1A) have shown that these molecules play an important role in T-cell-mediated help for humoral immunity \[[@kex078-B3], [@kex078-B4]\] a key process in lupus pathogenesis.

The SLAM gene family comprises functionally related cell-surface type I transmembrane receptors, which are expressed broadly on haematopoietic cells, including T, B and NK cells, myeloid and plasmacytoid dendritic cells, macrophages and monocytes. Members of this family are as follows: CD150 (SLAMF1), CD48 (SLAMF2), CD229 (SLAMF3, Ly-9), CD244 (SLAMF4, 2B4), CD84 (SLAMF5), NTB-A (SLAMF6) and CD319 (SLAMF7, CRACC, CS1). With the exception of CD48, which interacts with CD244, all of the SLAM members interact via homophilic interactions. The SLAM receptors have immunoreceptor tyrosine-based switch motifs in their intracellular domain that can be bound by SH2D1A and Ewing's sarcoma-activated transcript 2 (SH2D1B). These interactions trigger important immunomodulatory effects \[[@kex078-B5], [@kex078-B6]\].

The SLAM gene cluster has been genetically associated with SLE in humans and in murine models of SLE. In humans, it is located within a chromosomal region, 1q23, that has been shown to have a strong linkage with SLE in genome-wide association studies \[[@kex078-B7]\]. Likewise, the syntenic linkage region on mouse chromosome 1 has been shown to be a genetic susceptibility region for the development of SLE in several spontaneous lupus-prone models \[[@kex078-B8]\]. For example, polymorphisms in the Ly108 gene (corresponding to SLAMF6 in humans) result in the generation of a Ly108 splice variant in lupus-prone mice that is involved in the pathogenesis of SLE \[[@kex078-B9]\]. Thus, emerging data provide strong arguments that these genes play an important role in key processes believed to lead to the development of SLE and therefore represent strong functional candidates.

LN is one the most serious clinical manifestations of SLE. It is a relapsing remitting GN that is treated with CS and immunosuppressive medications, all with a considerable side-effect burden for the patients. Thus, there is growing recognition of the need to identify marker(s) of disease flare/remission that will facilitate patient stratification according to prognosis and treatment. We explored whether expression of SLAM receptors on different T-cell subpopulations \[CD4, CD8 and double negative (DN) T cells\] could be used as a biomarker for LN. We analysed SLE patients with active LN and those in remission but with a history of LN. Unexpectedly, we found that patients who were clinically inactive displayed more noticeable changes in the expression of the SLAM gene family than the healthy individuals. Taken together, our data provide further support for the concept that SLAM molecules have important disease-modifying effect(s) in SLE.

Methods
=======

Patients
--------

Thirty SLE patients (all of whom met the revised ACR criteria \[[@kex078-B10]\] and the SLICC criteria \[[@kex078-B11]\]) with biopsy-proven LN were recruited from the Imperial Lupus Centre ([Table 1](#kex078-T1){ref-type="table"}). The LN subsets were categorized according to the International Society of Nephrology/Renal Pathology Society classification. Patients who had received CYC and/or B-cell depletion within 6 months were excluded. The BILAG index was used for clinical assessment and response. Active LN was defined as urine protein:creatinine ratio \>50 mg/mmol together with biopsy-proven class III or IV or V LN within 3 months of recruitment. Inactive LN was defined as patients with a history of biopsy-proven LN and on a prednisolone dose of ⩽10 mg daily together with renal BILAG domain grade D, protein:creatinine ratio \<20 mg/mmol and no change in SLE-related medication within 12 months before recruitment. The healthy volunteer cohort consisted of 4 males and 16 females, with a median age of 34 years (range 24--54 years). Samples from patients and healthy volunteers were collected as a sub-collection registered with the Imperial College Healthcare Tissue Bank (National Research Ethics Service approval 12/WA/0196). Informed consent was obtained from all contributing individuals according to the Declaration of Helsinki. The Tissue Management Committee of the Imperial College Healthcare Tissue Bank approved the application (ref R13010a) to use these samples in this study. T[able]{.smallcaps} 1Baseline characteristics of study cohortNumberLN classCurrent treatmentPrevious CYC (total dose, g)Previous RTX (total cycle number)**Protein: creatinine ratio**[^a^](#tblfn2){ref-type="table-fn"}**(mg/mmol)**SLEDAIBILAG/ renalSLE (LN) duration (years)Active    1III (A/C)MMF, HCQ00290813/A0 (0)    2IV-S (A)MMF, HCQ, Pred002231945/A8 (7)    3III (A)HCQ002891323/A0 (0)    4V + III (A)MMF, HCQ, Pred016041826/B1 (1)    5V + III (A/C)MMF, HCQ, Pred0077817/B1 (0)    6VMMF, HCQ, Pred0127088/B8 (8)    7V + III (C)MMF, HCQ0173268/B5 (4)    8III (C)MMF, HCQ, Pred319188/B12 (10)    9VMMF, HCQ, Pred611341213/A30 (30)    10V + III (A)MMF, HCQ002010734/A0 (0)    11IV-S (A/C)MMF, HCQ, Pred001611331/B6 (0)    12III (A/C)HCQ, Pred, i.v.MP×300831715/C8 (0)    13V + IV-S (A/C)AZA, Pred6112361013/A6 (5)    14IV-G (A)MTX, HCQ, Pred, i.m.MP×1012111330/B3 (3)    15V + IV-G (A/C)MMF, Pred30272812/A17 (17)    16V + IV-G (C)MMF, HCQ01398412/A7 (7)    17IV−G (C)HCQ, Pred00161414/A25 (24)    18VMMF30294812/A17 (13)    19III (A)MMF, HCQ31229813/A18 (12)Inactive    20IVAZA, Pred00\<2000/D35 (35)    21IVPred30\<2000/D28 (26)    22V + III (C)MMF, HCQ01\<2000/D29 (28)    23VMMF01\<2000/D11 (10)    24III (A)AZA, HCQ00\<2040/D15 (15)    25IIIHCQ00\<2021/D10 (10)    26IVHCQ31\<2000/D4 (4)    27VAZA, HCQ00\<2021/D30 (25)    28IIIAZA, HCQ01\<2031/D7 (7)    29IIINone01\<2022/D8 (8)    30IV-G (A)AZA, HCQ03\<2062/D11 (7)[^2][^3]

Ten out of the 19 active LN patients were treated with rituximab (anti-CD20 antibody). The rituximab regimen was two doses of rituximab (1 g) and methylprednisolone (500 mg) on days 1 and 15 \[[@kex078-B12]\]. In two patients, methylprednisolone was omitted because of concomitant oral prednisolone. Owing to rituximab hypersensitivity, one patient received ofatumumab (a fully humanized anti-CD20 antibody). Background immunosuppressive medications were continued if taken at baseline. Renal response to B-cell depletion at 12 months was defined as follows: protein:creatinine ratio decrease by \>50% from baseline, estimated glomerular filtration rate ⩾60 ml/min or if \<60 ml/min at baseline, not fallen by \>20% and improvement in overall disease activity scores (SLEDAI/BILAG). Patients not meeting these criteria at 1 year post B-cell depletion were defined as non-responders. Non-responders included patients who required treatment escalation.

Lymphocyte analysis by flow cytometry
-------------------------------------

Peripheral blood mononuclear cells, isolated from whole blood by density gradient centrifugation, were stained using the following panels: blood cell populations (efluor450 anti-CD3, FITC anti-CD4, APC-efluor 780 anti-CD8, PE-CY7 anti-CD19, PerCP-efluor 710 anti-CD14, PE anti-CD16 and APC anti-CD56); B-cell phenotype (efluor450 anti-CD3, PE-CY7 anti-CD19, PE anti-CD24, APC anti-CD27, FITC anti-CD38 and PerCP-efluor 710 anti-IgD); NK and NK T cells (APC or PE anti-CD56, PerCP-efluor 710 anti-CD16, efluor-450 anti-CD3, PE anti-Nkp30, PerCP-efluor 710 anti-Nkp44, APC anti-Nkp46, PE-CY7 anti-αβTCR and FITC anti-γδTCR); T-cell phenotype \[PE-CY7 anti-CD4, APC-efluor 780 anti-CD8, V500 anti-CD3 (BD Biosciences, San Diego, CA, USA), PerCP-efluor 710 anti-CCR7, FITC anti-CD45RA, efluor-450 anti-CD45RO and PE anti-CXCR5\]. SLAM receptor expression on T cells was determined as follows: V500 anti-CD3, PE-CY7 anti-CD4, APC-efluor 780 anti-CD8, PE anti-CD150, BV421 anti-CD48 (Biolegend, San Diego, CA, USA), APC anti-CD229, FITC anti-CD244, APC anti-CD84, PE anti-CD352 and PE anti-CD319. Gate strategies are illustrated in [supplementary Fig. S1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online. All antibodies were obtained from e-Bioscience (San Diego, CA, USA) unless noted differently. Non-specific Fc-mediated interactions were blocked with human Fc receptor binding inhibitor. Flow cytometry was performed with a BD FACSVerse (BD Biosciences). Data were analysed using FlowJo software, version 10 (TreeStar, Ashland, OR, USA).

Statistical analysis
--------------------

Results were expressed as the mean ([s]{.smallcaps}.[d]{.smallcaps}.) or median with interquartile range. Comparisons between two groups were performed using the Mann--Whitney *U*-test, between more than two groups using the analysis of variance with Tukey's multiple comparison test. A value of P \< 0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism version 7.0 (GraphPad Software, San Diego, CA, USA).

Results
=======

Baseline clinical characteristics and cellular phenotyping
----------------------------------------------------------

A cohort of 30 biopsy-proven LN patients was evaluated. Demographic features and baseline clinical scores are shown in [Table 1](#kex078-T1){ref-type="table"}. The median age of the patients was 34.5 years, and the disease duration ranged from 0 to 35 years (8 years). Only three patients were males. Among the 30 LN patients, 19 had active LN and 11 had inactive LN. Median age and disease duration as well as the distribution of sex and ethnic background were similar in the active and inactive LN patients. The LN histological classes were also equally distributed between the two groups.

We initially assessed the distribution of the peripheral blood subpopulations ([Table 2](#kex078-T2){ref-type="table"}). As expected, lupus patients displayed several cellular changes compared with the healthy controls. The most notable differences included a significant decrease in the frequency of NK cells; in particular, of the CD56^Dim^ NK fraction among the NK cells; and a strikingly increased percentage of naïve B cells. These changes were independent of the disease activity at the time of the analysis. T[able]{.smallcaps} 2Flow cytometry analysis of peripheral blood mononuclear cellsCell population (%)Flow cytometry stainingGroupP-valueAIHDA *vs* IA *vs* HDI *vs* HD(n = 19)(n = 11)(n = 21)Total CD3CD3^+^47.84 (16.87)53.70 (16.17)56.19 (10.22)0.53030.16690.8872CD4CD3^+^ CD4^+^38.23 (20.50)33.82 (18.40)45.83 (14.55)0.79090.37500.1757Central memory CD4CD3^+^ CD4^+^ CD45RA^−^ CCDR7^+^18.74 (9.36)28.38 (5.99)32.75 (13.90)0.09150.0008[\*](#tblfn4){ref-type="table-fn"}0.5918Effector CD4CD3^+^ CD4^+^ CD45RO^+^8.24 (5.85)1.72 (0.91)7.22 (6.61)0.0185[\*](#tblfn4){ref-type="table-fn"}0.84350.0514Naïve CD4CD3^+^ CD4^+^ CD45RA^+^ CCDR7^+^29.73 (14.86)39.34 (15.76)26.51 (9.66)0.19900.72350.0592Follicular CD4CD3^+^ CD4^+^ CXCR5^+^8.5 (4.60)9.14 (4.47)13.43 (4.97)0.93210.0058[\*](#tblfn4){ref-type="table-fn"}0.0500[\*](#tblfn4){ref-type="table-fn"}CD8CD8^+^ CD8^+^29.98 (17.01)20.98 (14.66)23.46 (11.17)0.23500.34150.8910Central memory CD8CD3^+^ CD8^+^ CD45RA^−^ CCDR7^+^3.16 (5.21)3.87 (1.45)4.56 (4.94)0.92370.61660.9277Effector CD8CD3^+^ CD8^+^ CD45RO^+^27.59 (13.42)19.59 (17.63)27.98 (14.11)0.37050.99610.3307Naïve CD8CD3^+^ CD8^+^ CD45RA^+^ CCDR7^+^37.92 (21.12)56.92 (31.18)31.49 (13.32)0.06980.59770.009DNCD3^+^ CD4^−^ CD8^−^5.75 (3.43)3.68 (1.77)5.25 (3.34)0.19450.86880.3786Ratio CD4/CD81.49 (0.74)2.23 (1.77)2.27 (1.04)0.21730.09590.9945NKCD3^−^ CD56^+^6.57 (3.26)6.23 (4.84)14.12 (7.94)0.98730.0006[\*](#tblfn4){ref-type="table-fn"}0.0023[\*](#tblfn4){ref-type="table-fn"}CD56^Dim^ NKCD3^−^ CD56^Dim^ CD16^Bright^59.05 (15.22)58.05 (27.18)88.7 (5.77)0.9853\<0.0001[\*](#tblfn4){ref-type="table-fn"}\<0.0001[\*](#tblfn4){ref-type="table-fn"}CD56^Bright^ NKCD3^−^ CD56^Bright^ CD16^Low^7.86 (4.95)9.45 (11.04)2.62 (2.63)0.78100.0333[\*](#tblfn4){ref-type="table-fn"}0.0157[\*](#tblfn4){ref-type="table-fn"}NKTCD3^+^ CD56^+^1.51 (1.66)1.17 (1.08)2.85 (3.81)0.93960.27540.2284Total BCD3^−^ CD19+6.97 (7.23)4.42 (1.73)7.09 (11.42)0.71230.99890.6850Early memory BCD3^−^ CD19^+^ IgD^+^ CD27^+^3.37 (3.88)8.57 (10.91)17.19 (12.90)0.35780.0002[\*](#tblfn4){ref-type="table-fn"}0.0634Late memory BCD3^−^ CD19^+^ IgD^−^ CD27^+^17.67 (14.07)20.57 (22.78)35.36 (27.16)0.93590.0407[\*](#tblfn4){ref-type="table-fn"}0.1838Naïve BCD3^−^ CD19^+^ IgD^+^ CD27^−^66.39 (21.78)66.61 (34.92)1.83 (1.73)0.9996\<0.0001[\*](#tblfn4){ref-type="table-fn"}\<0.0001[\*](#tblfn4){ref-type="table-fn"}Plasma cellsCD3^−^ CD19^+^ IgD^−^ CD27^+^ CD38^+^20.17 (19.26)8.99 (9.10)5.27 (4.78)0.07000.0023[\*](#tblfn4){ref-type="table-fn"}0.7279Transitional BCD3^−^ CD19^+^ IgD^High^ CD27^−^ CD38^High^ CD24^High^8.48 (7.10)3.7 (5.14)5.29 (3.99)0.07250.18800.7301MonocytesCD14^+^17.18 (8.75)11.52 (3.59)9.80 (3.13)0.0422[\*](#tblfn4){ref-type="table-fn"}0.0011[\*](#tblfn4){ref-type="table-fn"}0.7285[^4][^5]

Patients with active LN had an increased frequency of plasma cells, whereas the percentages of early memory B cells, follicular and central memory CD4 T cells were reduced compared with those in healthy donors. Of note, an increased monocyte proportion was the only feature that distinguished active LN from both inactive LN and controls ([Table 1](#kex078-T1){ref-type="table"} and [supplementary Fig. S2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online). This relative increase is likely to be the result of the more severe lymphopenia in patients with active disease.

SLAM receptors on DN and CD8 T cells---potential biomarkers of renal disease activity
-------------------------------------------------------------------------------------

Previous reports have shown that the SLAM gene family may act as an important alternative pathway for T-cell co-stimulation and that certain members are expressed abnormally in peripheral blood mononuclear cells from SLE patients \[[@kex078-B13]\]. To assess this in our patient cohort, we analysed all SLAM receptors on the three main T-cell subpopulations: CD4, CD8 and DN cells. Owing to technical limitations, we aborted the assessment of SLAMF1 expression after the analysis of the first 12 patients. At this stage, there were no differences between the three experimental groups (data not shown). The study of the remaining SLAM members, SLAMF2--SLAMF7 inclusive, is presented in [Table 3](#kex078-T3){ref-type="table"}, and the most informative findings are shown in [Fig. 1](#kex078-F1){ref-type="fig"}. The most prominent differences were noted in the percentages of DN and CD8 T cells expressing SLAM receptors. The frequency of DN T cells positive for SLAMF2, SLAMF4 or SLAMF7 was markedly altered in SLE patients, but these differences were unrelated to the disease activity. In contrast, the proportion of CD8 T cells expressing SLAMF3, SLAMF5 or SLAMF7 was significantly lower in the lupus patients in clinical remission compared with the other two groups ([Fig. 1](#kex078-F1){ref-type="fig"}A). A repeated analysis using samples taken at a different time from a small number of individuals showed consistent results, demonstrating that the changes were stable (data not shown). Differences in the expression of SLAMF2, SLAMF3 or SLAMF4 were also noticed, but these changes were less obvious and did not show a clear pattern ([Fig. 1](#kex078-F1){ref-type="fig"}B). Overall, in comparison with healthy controls, the differences in expression were more marked in the inactive rather than the active LN patients. T[able]{.smallcaps} 3Analysis of signalling lymphocyte activation molecule receptors on CD4^+^, CD8^+^ and double negative T cellsFrequency of positive cellsIntensity of expressionSLAMCell population%P-valuesMFIP-valuesAIHDA *vs* IA *vs* HDI *vs* HDAIHDA *vs* IA *vs* HDI *vs* HD(n = 19)(n = 11)(n = 20)(n = 19)(n = 11)(n = 20)SLAMF2 (CD48)CD4^+^73.38 (32.44)65.31 (23.55)82.89 (20.15)0.71850.52900.21912919 (783.7)3091 (635.0)2421 (348.1)0.75790.0490[\*](#tblfn6){ref-type="table-fn"}0.0220[\*](#tblfn6){ref-type="table-fn"}CD8^+^52.02 (28.78)43.58 (28.60)49.64 (24.57)0.71240.96260.83902381 (594.2)2718 (383.3)2094 (376.8)0.16090.16600.0031[\*](#tblfn6){ref-type="table-fn"}DN93.03 (10.82)93.66 (6.30)44.95 (25.17)0.9954\<0.0001[\*](#tblfn6){ref-type="table-fn"}\<0.0001[\*](#tblfn6){ref-type="table-fn"}1709 (679.3)1609 (600.1)2249 (351.6)0.89250.0148[\*](#tblfn6){ref-type="table-fn"}0.0148[\*](#tblfn6){ref-type="table-fn"}SLAMF3 (CD229)CD4^+^91.71 (15.20)78.68 (14.18)88.32 (18.27)0.09910.79400.2668451.8 (80.46)337.1 (39.86)448.3 (111.5)0.0037[\*](#tblfn6){ref-type="table-fn"}0.99150.0046[\*](#tblfn6){ref-type="table-fn"}CD8^+^81.14 (20.27)3.93 (3.45)70.85 (37.22)\<0.0001[\*](#tblfn6){ref-type="table-fn"}0.4607\<0.0001[\*](#tblfn6){ref-type="table-fn"}556.8 (198.7)435.6 (79.88)366.1 (64.60)0.39110.0241[\*](#tblfn6){ref-type="table-fn"}0.0018[\*](#tblfn6){ref-type="table-fn"}DN73.66 (23.15)59.27 (12.86)76.62 (24.77)0.20590.91230.1094495.8 (153.4)544.1 (51.22)630.1 (122.1)0.56840.0058[\*](#tblfn6){ref-type="table-fn"}0.1822SLAMF4 (CD244)CD4^+^1.97 (2.66)1.39 (1.90)0.96 (1.57)0.74860.30730.8555206.6 (48.66)209.9 (57.56)198.2 (21.63)0.97660.80990.7422CD8^+^37.08 (23.10)22.14 (20.49)41.38 (18.32)0.14890.79510.0442[\*](#tblfn6){ref-type="table-fn"}244.8 (43.43)208.6 (9.97)245.2 (33.75)0.0223[\*](#tblfn6){ref-type="table-fn"}0.99940.0195[\*](#tblfn6){ref-type="table-fn"}DN25.04 (14.18)20.53 (22.0)55.67 (19.66)0.5410\<0.0001[\*](#tblfn6){ref-type="table-fn"}\<0.0001[\*](#tblfn6){ref-type="table-fn"}285.9 (77.06)226.5 (21.38)265.2 (44.47)0.0249[\*](#tblfn6){ref-type="table-fn"}0.27290.1578SLAMF5 (CD84)CD4^+^56.41 (9.49)48.39 (16.88)51.83 (13.56)0.27080.52710.7746366 (99.88)336.3 (88.91)399.5 (91.58)0.70580.52400.2056CD8^+^54.71 (38.80)6.49 (9.17)37.70 (33.53)0.0015[\*](#tblfn6){ref-type="table-fn"}0.11480.0341[\*](#tblfn6){ref-type="table-fn"}472.2 (202.6)494.9 (382.1)466.8 (135.1)0.96570.99710.9462DN T76.06 (14.17)72.27 (14.19)65.89 (12.33)0.75770.07220.4595432.3 (130.7)345.9 (62.67)432.5 (143.1)0.198610.1974SLAMF6 (CD352)CD4^+^52.34 (23.27)29.26 (22.39)36.59 (26.70)0.0459[\*](#tblfn6){ref-type="table-fn"}0.13560.71171617 (429.4)1324 (205.4)1545 (559.4)0.21930.88190.4059CD8^+^55.55 (22.05)31.62 (31.97)45.05 (28.63)0.06600.47440.40031976 (516.6)1600 (211.7)1950 (695.7)0.18620.98850.2251DN65.96 (19.14)47.37 (31.08)56.69 (39.71)0.27400.64760.71631943 (476.1)1634 (217.6)1970 (714.8)0.30740.98760.2494SLAMF7 (CD319)CD4^+^13.35 (30.69)2.55 (4.54)12.72 (23.10)0.56610.93530.5661628.5 (426.9)379.5 (78.29)410.9 (144.4)0.05880.05880.7677CD8^+^39.22 (30.28)13.13 (12.81)43.72 (15.67)0.0084[\*](#tblfn6){ref-type="table-fn"}0.79990.0016[\*](#tblfn6){ref-type="table-fn"}559.4 (469.6)327.5 (59.54)362 (47.23)0.10380.10070.9477DN34.61 (28.25)27.17 (21.05)63.94 (13.44)0.64880.0006[\*](#tblfn6){ref-type="table-fn"}0.0002[\*](#tblfn6){ref-type="table-fn"}584.8 (397.9)371.6 (75.72)399.3 (67.50)0.08470.08370.9576[^6][^7]

![Cellular analysis of signalling lymphocyte activation molecule receptors on T cells\
Total T cells from 20 healthy donors and 19 active and 11 inactive LN patients were analysed for surface SLAM receptor expression by flow cytometry. (**A**) Frequency of SLAM receptor-positive T cells. (**B**) Mean fluorescence intensity of SLAM receptors. Bars represent median with interquartile range. P-values were determined by one-way analysis of variance with Tukey's multiple comparison test: \*P \< 0.05, \*\*P \< 0.005, \*\*\*P \< 0.0005 and \*\*\*\*P \< 0.0001. DN: double negative; MFI: mean fluorescence intensity; SLAM: signalling lymphocyte activation molecule.](kex078f1){#kex078-F1}

SLAMF6 expression as a potential predictor of the clinical response of LN to B-cell depletion
---------------------------------------------------------------------------------------------

During the course of the study, a subset of patients (n = 11) with active LN received a B-cell depletion therapy. As we had detected marked differences in the expression of the SLAM receptors on T cells between SLE patients and controls, we explored whether the SLAM cellular phenotype was correlated with the clinical response to B-cell depletion. The clinical features of this subset cohort before B-cell depletion and at 12 months are shown in [Table 4](#kex078-T4){ref-type="table"}. Five out of the 11 patients were classified as responders using the criteria described in the Methods section. The remaining six patients required CYC because of clinical deterioration. Having established the pattern of response among the patients, we then assessed whether the frequency of the SLAMF-positive DN T cells could have predicted the clinical outcome at baseline. Our data showed that the LN patients who failed to achieve clinical remission had a higher frequency of SLAMF6 DN T cells at baseline (P = 0.0303; [Fig. 2](#kex078-F2){ref-type="fig"}). Consistent with the notion that these non-responders might have a more refractory renal disease, co-engagement of SLAMF6 on DN T cells has previously been shown to result in the production of greater amounts of pro-inflammatory cytokines, such as IFN-γ and TNF-α, compared with co-stimulation with anti-CD28 \[[@kex078-B13]\]. T[able]{.smallcaps} 4Characteristics of the study cohort treated with B-cell depletionNumberLN classBaseline treatmentRituximab**Protein:creatinine ratio**[^a^](#tblfn8){ref-type="table-fn"}**(mg/mmol)**SLEDAIBILAG/renalEnd point (months)**RespondersRegimenCycle**[^b^](#tblfn9){ref-type="table-fn"}**Baseline+12 monthsBaseline+12 monthsBaseline+12 months**10V + III (A)MMF, HCQRTX + i.v. MP×2120103877434/A12/B1211IV-S (A/C)MMF, HCQ, PredRTX1161\<2013331/B2/D1212III (A/C)MMF, HCQ, Pred, i.v. MP×3RTX + i.v. MP×2183\<2017415/C3/D1214IV-G (A)MTX, HCQ, Pred, imMPx1RTX + i.v. MP×222119013630/B3/C1213V + IV-S (A/C)AZA, PredRTX + i.v. MP×22123618910313/A2/C12**Non-respondersRegimenCycle**[^b^](#tblfn9){ref-type="table-fn"}**BaselineAt flareBaselineAt flareBaselineAt flareTime of flare (months)**1III (A/C)MMF, HCQRTX + i.v. MP×212902758813/A22/A32IV-S (A)MMF, HCQ, PredRTX1223198191445/A22/A13III (A)HCQRTX + i.v. MP×2128924312623/A14/A34V + III (A)MMF, HCQ, PredOfatumumab2604382182226/A19/A119III (A)MMF, HCQRTX + i.v. MP×222294858913/A13/A37V + III (C)MMF, HCQRTX + i.v. MP×237321469678/B9/B3[^8][^9][^10]

![Frequency of double negative T cells expressing SLAMF6 at baseline\
Comparison of the percentage of SLAMF6-positive DN T cells between responders and non-responders. Response to B-cell depletion was determined at 12 months post-infusion. P-values were determined by the Mann--Whitney *U*-test: \*P = 0.0303. DN: double negative; SLAM: signalling lymphocyte activation molecule.](kex078f2){#kex078-F2}

Discussion
==========

The importance of the SLAM receptors in SLE derives from their broad expression and their immunomodulatory roles in the cross-talk between a number of immune cells \[[@kex078-B6]\]. We focused our analysis on T-cell expression of SLAM receptors in a cohort of SLE patients with biopsy-proven nephritis categorized into those with active and those with inactive LN. Our data showed that patients in clinical remission have markedly reduced percentages of CD8 T cells expressing SLAMF3, SLAMF5 or SLAMF7. This may indicate decreased CD8 T-cell activation. In contrast, changes in the frequency of the SLAMF2-, SLAMF4- and SLAMF7-positive DN T cells, which share a gene expression profile with the CD8 T cells, distinguished the lupus patients from healthy controls. However, these changes were independent of nephritis activity. We also found a higher proportion of CD352^+^ (SLAMF6) DN T cells in patients with active LN who subsequently failed to improve with B-cell depletion therapy. The engagement of SLAMF6 can prime T cells to produce Th1 cytokines, especially from CD8 and DN T cells \[[@kex078-B13]\]. We speculate that the higher frequency of SLAMF6^+^ DN T cells, through enhanced Th1 cytokine production, reflects a more aggressive LN phenotype. If confirmed, this may have clinical utility as a biomarker when deciding between B-cell depletion therapy and CYC regimens. There is a need for additional biomarkers beyond histological phenotyping, because it is clear from our data ([Table 4](#kex078-T4){ref-type="table"}) and others that the sub-type of LN is not correlated with treatment response \[[@kex078-B17], [@kex078-B18]\].

Unsurprisingly, in our lupus cohort we observed several cellular changes that mirror published findings. In agreement with previous reports \[[@kex078-B19], [@kex078-B20]\], we found a higher frequency of naïve B cells, defined as CD19^+^ IgD^+^ CD27^−^, in the SLE patients compared with healthy controls. This increase was irrespective of the disease activity, in keeping with the notion that even inactive SLE patients fail to remove self-reactive naïve B cells \[[@kex078-B21]\]. In contrast, studies have reported that the CD27^−^ naïve B-cell subpopulation is markedly reduced in the peripheral blood of lupus patients \[[@kex078-B22], [@kex078-B23]\]. The heterogeneity of CD27^−^ B cells, previously thought to represent exclusively naïve B cells, has recently become apparent, and thus the CD27^−^ population may also contain memory B cells \[[@kex078-B24]\]. The use of these different markers makes it difficult to compare studies. However, in the active SLE patients we observed a reduction in the percentage of antigen-experienced CD27^+^ memory B cells, a finding that is in conflict with other studies \[[@kex078-B25]\]. Memory B cells are less susceptible to immunosuppressive therapy because they are not highly proliferative and conventional immunosuppressive drugs depend on cell cycling. We speculate that our findings may reflect the fact that many of our patients had a long history of LN and had been treated with B-cell-depleting therapy. It might be that repetitive anti-CD20 treatment cycles results in more substantial depletion of the memory B-cell compartment compared with non-B-cell-depleting immunosuppressive regimens. Independently, memory B cells can easily differentiate into plasma cells because they have lower activation thresholds. Consistent with this, we found a significantly increased fraction of plasmablasts/plasma cells in the SLE patients with active LN. This is in agreement with reports showing strong correlations between the frequencies of plasma cells and disease activity \[[@kex078-B26]\] or the time of clinical relapse after B-cell-depleting therapies \[[@kex078-B27], [@kex078-B28]\]. Another striking difference between the patients and the healthy controls was the marked reduction of the total NK cell frequency. Specifically, the CD56^Dim^ fraction, which is the most abundant one, was reduced, whereas the CD56^Bright^ was slightly increased. Although numerical and functional defects in NK cells have been described previously \[[@kex078-B29]\], the NK cell lymphopenia seems to be a key feature of SLE patients with renal involvement \[[@kex078-B34]\]. Whether this is the result of the migration of the CD56^Dim^ NK cells, a cell type with high cytotoxic capacity, into the inflamed kidney can only be speculated without further studies at the site of tissue damage.

Several studies have explored the expression of the SLAM receptors on immune cells from SLE patients, but the results are variable. This is likely to reflect the heterogeneity of SLE. To address this, we chose to study SLE patients with biopsy-proven LN. Our cohort was well characterized and our definitions of active and inactive LN were rigorous to enable us to explore reliably whether LN disease activity and the response of LN to B-cell depletion were associated with differential expression of T-cell SLAM genes. The SLAM receptors are important alternative pathways of T-cell co-stimulation. Consequently, it is not surprising that we found several abnormalities in SLE T cells. However, the most striking abnormalities were detected in the CD8 and DN T cells rather than CD4 T cells. CD8 and DN T cells are closely linked populations, because at least some of the DN cells may represent CD8 subsets that have lost CD8 from the surface membrane \[[@kex078-B35], [@kex078-B36]\]. Although the DN T-cell population was not expanded in our SLE cohort, the proportions of SLAMF2-, SLAMF4- and SLAMF7-expressing cells were significantly different in the lupus patients, regardless of the disease activity, compared with the healthy controls. Consistent with our observation a study by Kis-Toth *et al.* \[[@kex078-B14]\] showed that SLE patients had significantly fewer SLAMF4-expressing CD8 T cells compared with healthy controls and that these cells were functionally impaired. Interestingly, these cells had an increased propensity to lose CD8 and to become DN T cells, spontaneously as well as upon activation. Furthermore, a reduced proportion of NK cells and monocytes positive for SLAMF4 was reported by Kim *et al.* \[[@kex078-B16]\], and a single nucleotide polymorphism of SLAMF4 has been associated with the presence of renal and neuropsychiatric manifestations in SLE patients \[[@kex078-B37]\]. SLAMF4 is known to interact with high affinity with SLAMF2 (CD48), and this interaction can mediate both activating and inhibitory pathways, depending on the cell type and the experimental conditions. It is thus intriguing that we found an increased proportion of SLAMF2-expressing DN T cells in the SLE patients, a finding that may indicate a compensatory mechanism.

Our study also revealed a striking loss of CD8 T cells expressing SLAMF3, SLAMF5 or SLAMF7 in the lupus patients in clinical remission. In keeping with the recent notion that an exhausted CD8 T-cell signature may predict good clinical outcome \[[@kex078-B38], [@kex078-B39]\], these changes may represent an exhausted cellular distribution. Previous studies on the expression and role of SLAMF3, SLAMF5 and SLAMF7 in SLE have focused on CD4 T cells, plasmacytoid dendritic cells or NK cells and highlighted how the ligation of these receptors may promote prolonged inflammation and tissue damage \[[@kex078-B15], [@kex078-B40]\]. Interestingly, it has been shown that plasmacytoid dendritic cells from SLE patients have lower expression of SLAMF5 and SLAMF7, whereas SLAMF3 is decreased on CD56^dim^ NK cells. More importantly, their expression was found to be upregulated by RNA-containing ICs, and these may trigger increased IFN-α secretion, promoting disease development \[[@kex078-B15]\]. Therefore, it is tempting to speculate that the lower frequency of SLAMF3-, SLAMF5- and SLAMF7-positive CD8 T cells in clinically inactive patients may reflect the reduced activation by pathogenic RNA-containing ICs. At the same time, these changes might decrease the activation threshold of these cells, acting as a negative feedback mechanism that helps to maintain the clinical remission. Further studies on the precise function of these SLAM receptors on CD8 T cells will be required to prove this formally.

The efficacy of B-depleting therapies in SLE remains controversial, with contradictory results from open-label and randomized controlled trials \[[@kex078-B41]\]. Even in studies that have demonstrated a benefit from treatment with rituximab, there has been considerable variability in initial response and time to relapse. We therefore explored whether the cellular expression of the SLAM family receptors could be a valuable predictive marker of renal response to B-cell depletion and help to apply B-cell-depleting agents more effectively. By monitoring the response at 1 year in a small cohort of LN patients, we found that patients with more circulating SLAMF6-expressing DN T cells before treatment failed to respond to B-cell depletion and required additional immunosuppressive therapy. In our study, as in a previous report \[[@kex078-B13]\], the expression of SLAMF6 on the surface of the T-cell subpopulations analysed was comparable between the SLE T cells and the normal T cells. However, the proportion of SLAMF6-expressing CD4 T cells was higher in the active lupus patients compared with the patients in remission. Interestingly, the SLAMF6-driven co-stimulation has been shown to be defective in SLE T cells. The defect was more pronounced in CD8 and DN T cells that also appear to produce more cytokines following engagement of SLAMF6 \[[@kex078-B13], [@kex078-B40]\]. Although it is tempting to propose that the frequency of SLAMF6^+^ DN T cells could help to identify LN patients requiring aggressive immunosuppressive regimens, such as CYC, it is also important to recognize that our finding could be relevant for only a small group of patients and thus have a limited value in clinical practice. Future studies in other LN cohorts are needed to validate the use of SLAMF6 on DN T cells as a predictive biomarker of response to B-cell depletion.

In summary, by analysing a selective group cohort of SLE patients with biopsy-proven LN we discovered several abnormalities in the SLAM family receptors on T lymphocytes. We identified a selective loss of CD8 T cells expressing SLAMF3, SLAMF5 or SLAMF7 in the lupus patients in clinical remission. In addition, we have shown that SLAMF6 on DN T cells could be a useful marker for assessing the response to B-cell depletion therapy. Overall, our study provides further support to the notion that the SLAM gene family plays a crucial role in lupus pathogenesis.
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[^1]: Victoria Stratigou and Anne F. Doyle contributed equally to this study.

[^2]: CYC and RTX refer to treatments given at least 6 months before this study. LN duration was calculated from the time of the first renal biopsy.

[^3]: The protein:creatinine ratio normal range is \<20 mg/nmol. MP: methylprednisolone; Pred: prednisolone; RTX: rituximab.

[^4]: Results are expressed as the mean (±[s]{.smallcaps}.[e]{.smallcaps}.[m]{.smallcaps}.). The P-values were considered statistically significant when P \< 0.05 according to one-way analysis of variance with Tukey's multiple comparison test.

[^5]: \*Significant P-values. A: SLE patients with active LN; DN: double negative T cells; HD: healthy donors; I: SLE patients with inactive LN; NKT: natural killer T cells; n: total number of patients in the group.

[^6]: Frequency of positive cells and intensity of expression. Data are from healthy donors and active and inactive LN patients. Results are expressed as the mean ([s]{.smallcaps}.[e]{.smallcaps}.[m]{.smallcaps}.). The P-values were considered statistically significant when P \< 0.05 according to one-way analysis of variance with Tukey's multiple comparison test.

[^7]: \*Significant P-values. A: SLE patients with active LN; HD: healthy donors; I: SLE patients with inactive LN; SLAM: signalling lymphocyte activation molecule.

[^8]: All patients received two infusions of 1000 mg of RTX or the fully humanized CD20 monoclonal ofatumumab with hydrocortisone to prevent infusion reactions. Patients defined as non-responders were treated with CYC at the time of flare.

[^9]: The protein:creatinine ratio normal range is \<20 mg/nmol.

[^10]: Cycle number indicates total number of cycles received, including the one during this study. MP: methylprednisolone; Pred: prednisolone; RTX: rituximab.
